

Capmatinib

03/20


ALTERNATE NAMES:

INC280; INCB28060; INC28060; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide

CATALOG #:

B3005-5 5 mg B3005-25 25 mg

STRUCTURE:



MOLECULAR WEIGHT:	412.4
CAS NUMBER:	1029712-80-8

APPEARANCE: Yellow solid powder

PURITY:

SOLUBILITY: ~1 mg/ml in DMF ~0.3 mg/ml in DMSO

>98%

DESCRIPTION: Capmatinib is an ATP competitive inhibitor of c-MET kinase or hepatocyte growth factor receptor (HGFR). Binding of Hepatocyt Growth Factor to c-MET receptor causes activation of multiple downstream pathways. Capmatinib potently inhibits *in vitro* kinase activity with an IC₅₀ of 0.13 nM. It prevents HGF-stimulated H441 cell migration with an IC₅₀ value of ~2 nM. It inhibts c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

- HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
- REFERENCE: Liu, X., Wang, Q., Yang, G., et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 17(22):7127-38 (2011).

RELATED PRODUCTS:

Branebrutinib (Cat. No. B2998) Zanubrutinib (Cat. No. B2512) Avitinib (Cat. No. B2995) Avapritinib (Cat. No. B2999) Theliatinib (Cat. No. B3004)

DISCLAIMER:

FOR RESEARCH USE ONLY! Not to be used on humans.